Skip to main content
Premium Trial:

Request an Annual Quote

IDBS Acquires Quantrix to Include Modeling and Analytics Tools in its Life Science Offerings

Premium

IDBS said this week that it has acquired Quantrix, a business modeling and analytics company, in an all-cash transaction.

Under the terms of the acquisition, Quantrix will continue to operate as an independent business from its offices in Portland, Maine, and Chris Houle will stay on as CEO.

The financial terms of the acquisition were not disclosed. Both firms are privately held.

Quantrix provides business modeling and analytics software and services to customers in more than 50 countries. The company's Quantrix Modeler lets users explore multiple dimensions simultaneously, define formulas with words rather than coordinates, and create new scenarios without rewriting or restructuring models.

IDBS called the acquisition a "strategic step forward" and noted that the Quantrix technology is already licensed for use within IDBS E-WorkBook Suite, which lets users capture and store their research data.

Neil Kipling, CEO of IDBS, said that the "transaction allows us to accelerate the introduction of advanced modeling and analytics tools into our solutions … in pharmaceutical and healthcare informatics, such as translational medicine and preclinical development."

IDBS acquired InforSense, a high performance computing and large scale data mining company; in a similar all-cash transaction last year to boost its data integration and analysis offerings in the life science space.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.